Emergent BioSolutions (EBS) Net Income towards Common Stockholders (2011 - 2026)

Emergent BioSolutions' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 90.0% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at -$8.6 million (up 93.47% YoY), while the FY2025 annual figure was $52.6 million, up 127.6% from the prior year.
• Net Income towards Common Stockholders was $6.8 million for Q1 2026 at Emergent BioSolutions, up from -$54.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $114.8 million in Q3 2024 to a low of -$283.1 million in Q2 2024.
• Historically, Net Income towards Common Stockholders has averaged -$65.1 million across 5 years, with a median of -$49.5 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders slumped 4932.43% in 2023, then jumped 655.56% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$67.0 million in 2022, then gained by 26.12% to -$49.5 million in 2023, then jumped by 36.77% to -$31.3 million in 2024, then tumbled by 74.44% to -$54.6 million in 2025, then soared by 112.45% to $6.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $6.8 million (Q1 2026), -$54.6 million (Q4 2025), and $51.2 million (Q3 2025), per Business Quant data.